Topical treatment with JAK1-specific INCB039110 for 7 days continuously improved skin lesions regarding erythema, induration, scaling and size leading to a strongly reduced lupus-skin-activity-score (adapted CLASI score) compared to placebo-treated mice (Figures 4A,B). This evidence concerns the gene JAK1 and Erythema.